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Rhinoviruses: The Quest for a Cure
Michelle Gordon- Grunin
INTRODUCTION
Rhinoviruses, also known as Human Rhinovirus, abbreviated HRV, are one of the many 
causes of the common cold. In fact, around 50 percent of all cold are caused by rhinoviruses, 
with the other major candidates being coronaviruses, influenza A or B virus, and minor causative
agents like parainfluenza virus, respiratory syncytial virus, adenovirus, and enterovirus (Makela
and Puhakka, 1997). However, due to the complex molecular structure of rhinoviruses, a cure for 
the common cold caused by HRV is still in the making. Several new treatments have been 
discovered, impacting the virus as different stages of its life, hopefully to prevent those colds that
are cause by HRV. Most are still in the process of development, and some have adverse effects. 
Hopefully, in the near future, a cure will be developed, saving millions of people per year from
that annual plague. (Greenberg, 2003).
INTRPDUCTION TO RHINOVIRUS
Rhinoviruses, or Human Rhinovirus are one of the most commonly studies viruses today. 
(Bella and Rossmann, 1999). The rhinovirus is a fairly small virus, only 30 nanometers, and it
belongs to the Picornaviridae (pico means small, virdae, meaning virus) family of viruses. There
are approximately 110-115 serotypes of rhinovirus, serotype being the testing of microorganisms
for recognizable antigens on its surface. 
HRV 16, computer simulated model
developed by Purdue researchers
http://findit22.chipublib.org-Cold virus
Organization of the external viral proteins
VP1, VP2, and VP3 in the icosahedral shell
of HRV’s and other picornaviruses. Each
protein is repeated 60 times. The canyon is
shown shaded. Taken directly from
(Rossmann et al., 1999)
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Rhinovirus complexing with the ICAM
receptor allows entry into a host cell.
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These numerous serotypes are what are responsible for the reinfection process, since different
types could affect a person at different times without immune response. (Tolan, et al., 2007) 
according to a study done in 1997, when two hundred young adults were tested, 50 percent of the
colds found were cause by rhinovirus, and the rest were caused by varying other viruses, like
coronavirus, or influenza A and B virus. Bacterial infections that cause cold-like symptoms were
rare, leaving proof that the cold is almost exclusively a viral disease. (Makela and Puhakka, 
1997) According to studies, almost 30-50 percent of all adult colds, and 10-25 percent of colds in 
children are cause by rhinoviruses. (Bella and Rossmann, 1999) According to Stephen 
Greenberg, M.D., (2003), in 1996, the common cold was responsible for almost 20 million days
of missed work, 22 million days of missed school, and 27 million physician visits in the U.S. In 
1998, 76 million visits physicians were tracked up to the common cold, 50 percent of which is
caused by HRV. In the United States each year, consumers seeking relief from cold symptoms
spend $2 billiom-3 billion on over the counter products to prevent the common cold (Anzueto 
and Neiderman, 2003).
Rhinovirus is a non-enveloped virus that has only a single stranded, positive sense RNA
molecule as its genome. (McCoy, 2004) The capsid is almost spherical, icosahedral in shape, and 
symmetrical. It is about 300 Angstroms in diameter, (about 30 nm) and is composed of around 
sixty copies of viral proteins. Theses viral proteins, specifically, VP1, VP2, VP3, and VP4, make
up the surface of virus to create an exterior shell. VP4 specifically forms the interior or the
capsid, which is in direct contact with the viral RNA (Bella and Rossmann, 1999). In fact, when 
the rhinovirus structure (specifically HRV 14) was mapped, all of the hypotheses about the
structure were proven right (Rossmann, et al., 1985).
VPI, VP2, and VP3 each take the shape of an eight-stranded molecule, each with a beta-
pleated sheet structure, known as the beta-barrel, and the run anti-parallel to each other (Badger, 
et al., 1988). These fit together in a description like a ‘jelly roll’, and form the outer surface of




         
       
      
 
      
       
           
        
     
       
      
         
          
  
          
     
      
     
          
       
    
     
 
 
        
       
         
        
     
            
      
      
         
          
         
        
 
       
         
            
      
rhinovirus, at each five-fold vertex, the corners of the polygonal sphere, there is a ‘star-fish like’ 
protrusion or protuberance, made up of five copies of VPI, along with a 25 angstrom deep 
depression or canyon encircling it. This cavity is what makes the canyons. (Bella and Rossman, 
1999)
VP4 is also shorter in the HRV, only around 70 residues, or portions of a larger molecule, 
added on, instead of around 240- 290 residues, like VP1-3, and it is lacking in any special
structure. It is on the internal surface of the capsid, near the RNA, and has its N-terminus near 
the five-fold vertex, and the C-terminus near the three-fold axis of the capsid. VP4 is also 
covalently bonded to a myristic acid group, giving five symmetrically relates myristic acid 
groups near the five-fold vertex, and a channel running through the inner and outer surfaces of
the capsid (Smyth and Martin, 2001). The protuberances are antigenically diverse among the
different serotypes of the rhinovirus, making the canyons different as well (Talaro and Talaro, 
2002). VP1-3 contain the antigenic sites that are important for the host immune response, so if
they are diverse, that allows for reinfections (Greenberg, 2003).
As for the receptors on the VP molecules, the rhinovirus can be grouped into two-three
different types based upon receptors. The first major group, compromising around 91 serotypes
have a cell surface glycoprotein known as intracellular-adhesion molecule-1, known as ICAM-1. 
The minor group, around 10 serotypes, binds to molecules of LDLR, low density lipoprotein 
receptors. The last group has a receptor that is yet to be discovered (Bella and Rossman, 1999). 
The LDL receptor that HRV serotype 2 bound to is also known as alpha-2-macroglobulin 
receptor, or a low density lipoprotein receptor related protein (Hofer, et al., 1993) Dr. Michael
Rossmann, with Roland Ruecker at the University of Purdue in 1985 actually discovered the 3-D 
structure of the rhinovirus, and came up with the canyon hypothesis (Radetsky, 1991).
MODE OF TRANSMISSION AMONG HUMANS
The rhinovirus usually attacks the upper repertory tract in humans. It can be transferred 
either through aerosol, which is the inhalation of small particles of virus, or through direct
contact, by touching the nose with a contaminated hand. However, once it is inside the nose, it
moves to the nasopharynx, lodging in the nasal mucosa epithelia cells. It binds to ICAM-1, or an 
LDL receptor, and infection begins among the host, or human cells (McCoy, 2004). The
conjunctiva of the eye may be involved, but because HRV attaches to epithelial receptors, it is
less so (Tolan, et al., 2007) Contagious behavior would be construed as nose blowing, sneezing, 
physically touching environmental surfaces or tissues with the nasal secretions. Within a
household, 50 percent of the time infection spreads, but within a school, it ranges from 0 to 50 
percent, leading scientists to believe that it requires long-term contact to take effect (Tolan, et al., 
2007). The virus replicates in the ciliated cells in the nasal epithelium, although it has been found 
in research that the non-ciliated cells of the adenoid also may support HRV infection (Arruda, et
al., 1991).
Viral shedding occurs in large amounts, specifically, as Robert Tolan, M.D. states, ‘as many as 1 
million infectious virions present per mL of nasal washings’. This shedding can occur before the
host realized that he or she has a cold, and can last as long as 3-4 weeks after the HRV cold 




      
 
 
      
        
          
       
 
          
        
            
 
 
          
     
           
       
       
       
         
 
        
    
 
      
      
 
        
 
      
        
        
      
         
     
 
      
         
      
     
      
HRV strain that they have not previously encountered will develop an infection, and 75 percent
of those who are infected display symptoms (McCoy, 2004). 
SENSITIVITY
Uniquely among the common viruses, rhinovirus has a sensitivity to temperature. It can 
only thrive in a temperature between 33-35 degrees Celsius, unable to survive in a normal body 
temperature of 37 degrees Celsius. This also limits its choice of receptor binding, because it
needs the receptors in the upper respiratory tract, and not in the lower respiratory tract, which has
a higher temperature (Tolan, et al., 2007).
Rhinovirus also has a sensitivity to pH, because if the virus is swallowed, the decreased 
pH in the stomach will prevent infection. The rhinovirus capsid dissolves in low pH, which 
effectively destroys the virus (McCoy, 2004). It is stated that a pH of 3-5 renders that virus
unstable (Fiala and Guze, 1970).
SYPMTOMS
Although rhinovirus infections affect people around the world at all seasons, it seems to 
be epidemic in fall and spring times, causing doctors to prescribe unnecessary antibiotics, which 
contribute to antibiotic resistance in bacteria that were present at the time (Rotbart and Hayden, 
2000). Despite what a parent may tell a child, getting wet, chilled, or exposure to cold weather 
are not clinically proven to increase the likelihood of contracting HRV (Tolan, et al., 2007). 
However, according, to a study done in the fall months on 346 adults, 224 were diagnosed as
having a cold due to HRV, showing that rhinovirus is the largest contributing virus causing colds
during the fall months (Arruda and Pitkaranta, 1997). 
Symptoms may begin within twelve hours after infection, and start with the release of
cytokines to initiate an inflammatory response. This causes airway hyper-reactivity, and an 
influx of neutrophils in the nasal mucosa and secretions (Rotbart and Hayden, 2000). 
The incubation period normally is 1-3 days, and the most common symptoms are
rhinorrhea (runny nose), nasal stuffiness, and sneezing. Other symptoms could be a sore or 
scratchy throat, facial pressure, headache, cough, hoarseness, malaise, chills, or feverishness. 
Significant fever is uncommon in adults, but in infants and young children it is present more
often (Rotbart, H., Hayden, F., 2000).
HRV can also cause upper and lower respiratory tract complications. Acute otitis media
(AOM), could be caused by HRV induced infections, and most cases of acute sinusitis are
thought to be a secondary bacterial infection from a primary case of HRV. In children with 
AOM, viruses have been detected in 11-41 percent of middle ear fluids, and rhinovirus
constitutes 8 percent of that. In acute sinusitis, HRV has been detected in 40 percent of sinus
brushings (Rotbart and Hayden, 2000). According to Robert Tolan, M.D., (2007) 24 percent of
patients with AOM have rhinovirus in their nasopharyngeal secretions. 
HRV can also exacerbate asthma in adults and children. In a two-year study done in 
adults with asthma from 19-46 years of age, colds were associated with 71 percent of
exacerbations, and rhinoviruses are the most commonly identified pathogens, HRV also is
associated with lower respiratory tract infections. Up to 40 percent of exacerbations in patients




    
       
      
      
       
   
      
  
       

























associated with lower respiratory tract illnesses that required hospitalization, including 
bronchiolitis, and bronchopulmonary dysplasia (Rotbart and Hayden, 2000). HRV may also 
cause laryngotracheobronchitis in infants, and in cystic fibrosis patients, rhinovirus is the culprit 
for 57 percent of respiratory exacerbations (Tolan, et al., 2007).
VIRUS ACTION AND INFECTION ATTACHMENT
The rhinovirus attacks a host using the established mechanisms of viral infection. Firstly, 
the viral capsid interacts with specific receptors on the cell membrane. The receptor binding sires 
on rhinoviruses are inside the canyon made by VP1-4, which surrounds each ‘star-fish’, five-fold 
axis (Smyth and Martin, 2002). When neutralizing antibodies were tested against rhinovirus’ 
surfaces, it was discovered that the virus continued to evade antibody neutralization actions. The 
mutations in shape that caused this were located at four distinct antigenic surfaces, at the most 
exposed regions on the virus- on the rim of the canyon depressions. However, molecular residues 
at the bottom of the canyon are conserved, and immunologically secluded, and the canyon is too 
narrow to allow antibodies access to the receptor sites. This led to the discovery that the canyon 
is the receptor binding site, and that the rhinoviruses can hide their binding sites there, protecting 
them from antibody attack, while they created external residues to confuse the host’s immune 
surface. This is known as the canyon hypotheses (Bella and Rossmann, 1999 and 2000). This 
protects the virus from any immune response that counteracts its cell receptor binding.
This image from Branden & Tooze shows
the structure of an IgG immunoglobulin
molecule.
Fig 1. Domain structure if ICAM-1. Each Ig http://images.google.imgres?imgurl=http://pps 
domain is represented schematically by a 00.cryst.bbk.ac.uk/course/section11/IgG.gif&i 
circle closed by one or two disulfide bonds. mgrefurl=http://pps00.cryst.bbk.ac.uk/course/s 
Amino acid numbers indicate the beginning ection11/immunog.html&h=349&w=285&sz= 
and end of each domain. Approximate 19&hl=en&start=3&tbnid=SsURfzzb9uyQjM: 
locations of relevant binding sites are shown. &tbnh=¹20&tbnw=98&prev=images%3Fq%3 
Lollipop-shaped structures indicate N- Dimmunoglobulin%2B%26gbv%3D2%26vnu 






       
      
      
    
       
           
       
    
      
    
         
 
 
        
             
          
       
         
      
    
 
        
     
        
        
  
      
           
       
     
 
            
          
            
          
         
         
         
       
    
The ICAM-1 receptor is a glycoprotein cell adhesion molecule (hence, CAM), that has an 
extracellular component made up of immunoglobulin chains. Immunoglobulin (Ig) chains are the
building blocks of antibodies, molecularly described as two sets of beta-pleated sheets running 
antiparallel to each other and linked by disulfide bonds. ICAM-1 has five Ig chains, also known 
as domains, along with a transmembrane region into the cell, and a short cytoplasmic domain 
inside the host cell. It has been described as a lollipop structure, due to the several domains
connected (Bella and Rossmann, 1999). The ICAM molecule has five immunoglobulin like
domains, known as D1-D5 respectively. D2-D4 are glycosylated, and D1 is the primary binding 
site for rhinoviruses, and for the ligand that ICAM-1 binds naturally, known as lymphocyte
function-associated antigen 1 (Olsen, et al., 1993). Some rhinoviruses have been known to 
stimulate the ICAM-1 expression on host cells to increase the chance of infection (Tolan, et al., 
2007).
UNCOATING
When HRV attaches to the ICAM-1 receptor, this initiates entry into the host cell. During 
the un-coating stage of viral infection, the RNA across the host cell membrane into the cell, but
the actual mechanism is still not known for HRV (Bella and Rossman, 2000). ICAM-1 is a
transmembrane protein, and its two terminal ends show an Ig like-fold, solidifying the structure
hypothesis. On the tip of domain D1, there are three loops important for HRV binding, known as
DE, BC, and FG. HRV is usually specific by species, and does not recognize ICAM-1 in any 
other species other than human, and also ignores similar CAM receptors, like ICAM-2 or ICAM-
3 (Bella and Rossmann, 1999). 
Richard Colonno, a scientist from Merck Laboratories, actually was the first one to 
discover the I-CAM receptor, along with the receptor antibody to prevent HRV from bonding to 
the host cell. In a method known as “Colonno’s brute force method”, he performed 8,000 
different tests, and discovered that the I-CAM antibody prevented mice nasal cells from
becoming infected (Radetsky, 1991). Colonno discovered, using receptor antibody that he
developed, that HRV used the canyon to bind to its ICAM receptor, and discovered the location 
of the plaques and residues inside the canyon (Colonno, et al., 1985). 20 out of 24 HRV
serotypes tested proved positive for the ICAM receptor, and the I-CAM antibody that Colonno 
developed seemed to prevent receptor binding for 78 out of 88 serotypes tested (Colonno, et al., 
1985).
Uncoating is the second step on rhinovirus infection of a host cell. The HRV must have a
stable enough capsid to be able to transport itself to the host cell and bind with a cell receptor, 
but it also must be able to disassociate when needed to allow the RNA genome to enter the host
cell. However, research has shown that the crucial step for rhinoviruses is the loss of the VP4 
protein. It seems that the myristic acid that is covalently bonded to the VP4 terminal end can 
interact with the host cell membrane, causing the release of VP4, and the genome, allowing the
RNA to enter the cell. The acid lies near the inner edge of the five-fold channel, allowing the
genome to leave the capsid through the channel. However, the capsid must disassemble enough 




       
 
       
          
       
            
          
     
        
        
 
 
          
        
          
        
        
       
      
           
        
         
            
 
        
         
       
  
    
       
    
      
 
              
       
      
      
   
      
       
         
         
          
which acid conditions were introduced, or as with HRV16, a preparation of its receptor was
exposed to it, initiating uncoating (Smyth and Martin, 2002).
In addition, there is a canyon contained within VP1, known as a pocket, which is
hydrophobic. Structural analysis has shown that there is a fatty acid in the pocket, known as a
pocket factor. This pocket factor has an ‘inhibitory but reversible’ effect on uncoating. This
allows the pocket to stabilize the capsid until it is time for it to disassemble when faced with a
host cell. Residues inside the pocket become more stable, along with the N-terminal end of VP3, 
which allows the protein to stabilize (Smyth and Martin, 2002). This pocket factor fatty acid also 
protects the virus in between its cell to cell transit, between neighboring cells (Xing, et al., 2003). 
So, when the rhinovirus binds to the cellular receptor, it causes the virion particle to disintegrate, 
and the RNA genome is released directly into the host cell (Sompayrac, 2002).
REPLICATION
Replication is the next step in the viral infection process. The RNA moves through a
membrane pore that is generated by the N-terminals of VP1 and VP4, during the uncoating 
process. It has been suspected, but never proven, that the RNA leaves through one of the 12 
vertexes at the starfish shaped protuberances. It has been theorized that the virion undergoes
conformational changes after the RNA leaves, which leads to capsid disassembly, but it has
never been shown. ICAM-1 also locks the virus in an ‘open state’ so that the RNA can be
released without the virion folding in on itself. When the virus expands, by locking the ICAM
receptor in place, which allows for movement of the RNA out of the virion. Once the RNA exits, 
this leads causes rearrangements in the virion cell, namely that the VPI molecule twists, allowing 
for a larger molecule that eventually disintegrates (Xin, et al., 2003). The RNA genome is then 
injected into the cell from the acidic endosomes that internalize the virus, like the myristic acid 
groups of the VP4 (Smyth and Martin, 2002).
Rhinoviruses trigger a chemokine and cytokine response once they have entered and 
started infecting the cell. This response exacerbates the symptoms of the common cold, and some
asthma patients, due to the inflammation that results (Virus Weekly, 2007). The cytokines, 
specifically are interferon-gamma and interleurkin-6 and interleurkin-8, along with interleukin-1 
alpha. (Anzueto and Niederman, 2003). This leads to nasal discharge, nasal congestions, 
sneezing, and throat irritation (Tolan, et al., 2007). The immune response attracts immune cells, 
and sends chemical messages to neighboring blood vessels, causing leaking of capillaries, 
glandular secretion, and causes stimulation of nerve fibers. This causes the sneezing and 
coughing reflexes, in addition to a pain sense (McCoy, 2004).
The RNA rhinoviruses is a positive sense RNA, meaning that it serves as the viral
mRNA, and can be immediately translated by the host cell without involving DNA. The RNA
contains between 7500 to 8300 nucleotides, and encodes a single large polyprotein (Belsham and 
Sonenberg, 1996). The complete HRV genome has been mapped for rhinovirus-14, which has
634 non-coding nucleotides, 6537 coding nucleotides, and again a 47 nucleotide region of non-
coding nucleotides. The molecular structure of HRV is most closely associated with 
enteroviruses, another of the family picornavirdae (Stanway, et al., 1984). It is translated one
time by the ribosomes of the host cell, and then the polyprotein created divides itself up into 
several viral proteins. One viral protein created is the viral RNA polymerase, which then makes
complementary copies of the original viral RNA, which are negative strands, in the sense that
10
they are the exact opposite of the original strand. These copies of the viral RNA ar
again, so complementary, positive sense strands are then created, and translated 
viral proteins (Sompayrac, 2002). 
These new viral proteins then undergo processing by virus-encoded proteas
produce the mature virus proteins. This mature viral protein contains about 
polypeptides plus some partially processed products. Four of these proteins, wi
copies of each one, make up the virus capsid, and other proteins are involved 
(Belsham and Sonenberg, 1996). The virion capsid protects the many copies of th
the rhinovirus leaves the cell (Sompayrac, 2002). The virus inhibits the ho
transcription and translation, modifies or destroys the intracellular membranes of 
the organelles), destroys the cell itself through lysis, and finally releases the m
ready to infect the next cell (Belsham and Sonenberg, 1996). 
The RNA genome is replicated though a RDRP, a RNA-dependent RN
which is a double stranded RNA intermediate to help the replication process. 
ribosomes are taken over, and initiated by an IRES, an internal ribosome entry site 
Sonenberg, 1996). The IRES allows the ribosomes to begin translating the original 
without the “cap” structure normally present in a genome (Sopayrac, 2002). 
The 5’ terminal end, or UTR, untranslated coding region, of the RNA is unc
is unusual. The rhinovirus 5’ UTR is able to direct protein synthesis without mRN
referred to as an IRES, or a ribosome landing pad. The IRES is located about 150 b
initiation codon on the 3’ UTR, but the distance can be greatly modified with littl
on rhinoviruses. Rhinoviruses do translate poorly, due to the fact that they, unlike 
have a checking factor built in to check the nucleotides before translation (
Sonenberg, 1996). The process by which the cell recognizes the IRES sequence i
but many initiation factors as well as other specific cellular proteins help. Three
been identified so far, polypyrimidien tract binding protein, La auto antigen, and P
binding protein). The binding of PCBP to the ‘clover lead’ RNA at the 5’ end e
translation (Gamarnik and Adino, 1998). 
To prevent interference from the host cell, the HRV encodes a protein tha
normal cap-dependent initiation of the host cell. This shuts down all protein s
capped, cellular mRNAs, except from its own uncapped RNA genome. It only tak
hours for a rhinovirus to reproduce, and to make thousands of new viruses (Sompay
RNA positive sense replica
undergoes once inside t
http://www.flutrackers.com/f
php?attachmentid=325&d
tion, what HRV 
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IMMUNE RESPONSE
The body’s natural immune response does try to prevent the inhalation of these virions. 
HRV enters into the lowest part of the nasal cavity, and starts its replication there, without
moving deeply into the lower respiratory and digestive systems to be destroyed by the acidic
contents of the stomach. This internal defense prevents rhinoviruses from causing intestinal or 
gut infections. However, there is another defensive immune response. When cells are under 
attack by a virion, they produce ‘warning-proteins’ known as Interferon-alpha and interferon-
beta. Interferon binds to receptors on uninfected cells, alerting those cells to virion invasion. 
These cells then spontaneously destroy themselves, to limit the spread of the virus. It is the
presence of a large quantity of double stranded RNA in the cell that causes it to produce
interferon (Sompayrac, 2002). 
HRV however, has a way to deal with the interferon signaling problem. It interferes with 
the production of interferon by shutting down the host cell’s system for transporting interferon 
out of the cells. So, HRV infected cells produce very little interferon. This also means that HRV
has not built up any resistance to interferon as an anti-viral mechanism. HRV is mainly destroyed 
in the body by the innate immune system, by the phagocytes and NK cells, so that a rhinovirus
infection is usually over in a few days. This causes a problem, because the infection is over so 
quickly that the adaptive immune system, like the B and T lymphocytes, are not activated, and 
neutralizing antibodies are not created for that infection. So, there is no way to prevent a second 
rhinovirus attack, even from the same strain of HRV, because there were no antibodies created 
from the first attack. And, HRV uses antigenic drift, so there are over one hundred different
strains of HRV all around in the public. This is when mutations that are introduced during viral
replication are used to produce different strains of the same virus. A person can continue being 
re-infected several times over a matter of weeks (Sompayrac, 2002).
Macrophages do provide one helpful immune response to rhinoviruses, in that they 
produce interleukin-1, a cytokine that triggers a low fever. HRV can’t tolerate higher 
temperatures, so it can help control the spread of the virus (Sompayrac, 2002). Interleukin-1 
alpha, interleukin-6, and interleukin-8 have been found in nasal secretions, and are responsible
for most of the symptoms (Anzueto and Niederman, 2003).
TREATMENT FOR HRV AND NEW DEVELOPMENTS
Because of the canyon hypothesis, along with the ‘attack and surrender’ mode of
infection of the rhinovirus, a HRV vaccine is impossible, and even if it were possible, it would 
not be cost effective, due to the necessity of vaccination for over 100 different types of HRV, 
due to antigenic drift. However, anti-viral therapy has been developed for HRV.
The WIN-family of compounds are common anti-viral agents being tested as a defense
against HRV. They bind to the pocket in VPI, which is hydrophobic, preventing the virus from
binding to the host cell. Usually this pocket is filled with the ‘pocket factor’, a lipid compound, 





           
 
        
        
    
          
          
 
 
           
        
       
        
        
        
      
          
            
               
          
          
        
 
 
          
       
      
 
 
        
 
    
      
     
 
 
     
         
         
   
beta-barrel, producing an open conformation, and preventing capsid uncoating (Hadfield, et al., 
1999). There are currently nine WIN compounds being tested, yet only a few of them show
efficacious results (Pevear, et al., 1989). 
The WIN compounds generally contain three aromatic rings, known as A, B, and C. some
rhinoviruses’ pockets only interact with ring C, while others interact with A and B. Ring A is
usually a methylisoxazole ring, ring B, a substituted phenoxy group, and ring C, a five-member 
heteroatom ring (Zhang, et al., 2004). Variations in the pocket if the rhinovirus, like a more
hydrophobic ‘toe end’ of the pocket, and a more hydrophilic ‘heel end’, lead to the different
bindings of the WIN compounds, and lead to different efficacies (Hadfield, et al., 1999).
WIN 54954
The WIN 54594 molecule is an oral anti-viral compound that is active against
rhinoviruses and enteroviruses. It works by binding to the hydrophobic pocket inside the VP4 
protein on the capsid surface, preventing the replication of the virus by interfering with the virus
uncaoting process, and by changing the cell receptor site to not allow HRV to attach to the host
cell. When WIN 54594 was tested in cell experiments, it inhibited 80 percent of the rhinovirus
serotypes that were presented to it. As such, the developing scientists started to perform clinical
trials on WIN 549594. However, when WIN 54594 was tested by volunteers in two different
trials who were infected with HRV type 39 or type 23, it had minimal effect. The scientists that
developed it feel that the reason was that the human nasal epithelial cells did not take up 
sufficient amounts of the drug to make a real difference in the sire of the viral infection. If the
scientists refine the drug, it may have potent anti-viral effects (Turner, et al., 1992). It did reach 
phase II clinical trials, but due to the low efficacy in vivo, and some side effects, it was stopped 
(Hadfield, et al., 1999). The side effects included adverse effects of flushing and a rash 
(McKinlay, 2001).
WIN 52084
WIN 52084 is also another anti-viral molecule that attaches to the hydrophobic pocket in 
VPI on a rhinovirus capsid, preventing its attachment to the host cell, and limiting its uncoating 
mechanism. It also stabilizes the capsid, allowing it to be inactivated by temperature or acid 
related influences (Lewis, et al., 1998).
WIN 51711
WIN 51711 was a compound that bound to the viral capsid, specifically to the interior of
VPU, preventing the virion from binding to the host cell receptor (Sperber and Hayden, 1988). 
This WIN compound, known as disoxaril, had broad implications in inhibiting 
picornavirus activity, specifically HRV, and it interacts in a similar way to the other WIN
compounds. However, when it entered phase I clinical trials, it failed toxicity tests, leading it to 
be stopped (Hadfield, et al., 1999).
PLECONARIL
According to the research in the United States, in 1994, there were 66 million 
cases of the common cold, caused by HRV. Pleconaril, a new oral drug developed, is a small
molecule inhibition of rhinovirus that is developed for the entire picornavirus family (Pevear, et




      
          
        
        
      
    
          
      
     
 
      
      
      
       
        
          
     
 
 
     
       
     
         
    
     
         
         
        
 
    
       
      
     
     
          
     
        
        
         
 
 
5(trifluoromethyl)-, 2, 4-oxadiazol}. It integrated into the pockets of the capsid at VP4, and 
inhibits the viral capsid uncoating. Pleconaril blocks the attachment to the host cell receptors, 
which in turn, inhibits viral replication. It was the first anti-picornavirus compound to be
submitted to the FDA. In the clinical trials, it did reduce symptoms and duration of the colds, and 
with animals, it has penetrated the cells involved, and protected them. In phase II studies, it
showed reduction of symptoms significantly, as compared with the placebo (Anzueto and 
Niederman, 2003). It is a WIN compound, WIN 63843, and is a third generation of the original
two WIN compounds, WIN 51711 and WIN 54954, and is currently in phase III trials (Hadfield, 
Diana, and Rossmann, 1999). According to a 2004 report, it has been in the phase III trials, and 
is performing efficaciously (Zhang, et al., 2004). 
Pleconaril has been tested on 1024 individuals who received it three times daily, and 
reduced the time to heal 3.5 days, instead of seven days. Individual symptoms also resolved 
themselves sooner in time to heal 3.5 days, instead of seven days. Individual symptoms also 
resolved themselves sooner in the pleconaril patients. The side effects seemed to be similar for 
both those on pleconaril and those with the placebo, and as such, it really has no adverse effects. 
It has a clinical (due to the reduction of symptoms) and antiviral effect (Rotbart and Hayden, 
2000). However, because of safety concerns based upon potential drug-drug interactions, the
FDA did not approve pleconaril, but new formulations are being considered (Greenberg, 2003).
INTRANASAL INTERFERON
Interferon molecules have antiviral, anti- proliferative, and immunological effects, mostly 
associated with the ‘suicide’ response of infected cells. Scientists have developed a synthetic
copy, intranasal interferon-alpha2, (or intranasal interferon alfa-2 beta) which has activity against
natural rhinovirus infections. However it has not been beneficial in treatment, due to the severe
side effects of nasal irritation and bleeding (Anzueto and Niederman, 2003). In fact, after double-
blind trials had been performed with interferon alfa-2 beta, there were no differences in the
respiratory symptoms scores, and although there were less active viral particles in the nasal
washings from those receiving interferon, there were instances of nasal bleeding, and was
associated with toxicity to the volunteers (Hayden, et al., 1987). It still remains to be seen if
other interferons or other methods can prevent these effects (Sperber and Hayden, 1988). 
Interferon alpha administered intranasally through the major study worked very well in 
preventing HRV colds. Out of the 14 volunteers who received the placebo, 6 had definite
rhinovirus infections, while 0 out of 10 with the interferon-alpha2 had been infected. During the
third week of testing, interferon-dosed patients complained of nasal discomfort, nasal
obstruction, and/or blood tinged mucus. The results tend to indicate the prevention of infection 
entirely, but due to the long term side effects, it cannot be prescribed long term. It has been 
administered through a spray and through drops, and has had a huge anti-viral effect. With 
regard to the drops, and a lower dosage of interferon, there was no intolerance, and it did prevent
colds, but there were long term side effects. Possibly, for short term, this drug could be used 
(Farr, et al., 1984). However, due to the severe symptoms, it is not useful for treating the





       
       
         
      
         
 
      
   
      
        
     
         
         
 
       
           
         
       
             
     
          
       
      
          
        
        
    
     
     
       
    
       
       
      
      
     
        
     
 
 
           
             
 
Richard Colonno had discovered the difference in receptors among the different strains of
HRV, determining what we know commonly now, that there are two major receptors, and most
use ICAM-1. As many as 115 serotypes were discovered and out of the 24 tested, they all shared 
the same ICAM-1 receptor on the host cells (Abraham and Colonno, 1984). After Colonno used 
his “Brute Force Method’ to discover an antibody, but as the synthetic antibody was not
eventually cost effective, more scientists took on the race to find a different cure (Taubes, 1999).
Greve and McClelland discovered in 1989 the major HRV receptor on human nasal
epithelial cells, known as the intercellular adhesion molecule-1, abbreviated ICAM-1. They 
discovered it by sending monoclonal antibodies to the host cells, and they recognized the ICAM-
1 protein on the cell surface and bound to it (Greve, et al., 1989). They made the antibodies by 
injecting mouse cells with human HRV-infected cells, and so the mouse would then make
antibodies for all the proteins on the host-cells surface. When they finally discovered that one of
these monoclonal antibodies worked, it was against ICAM-1, already discovered as a cell
receptor molecule by Springer, another scientist working at his own laboratory (Taubes, 1999). 
Greves and McClelland, along with a different scientist, Hayden developed a synthetic of
what is commonly known as soluble ICAM-1, or sICAM-1, a form of the receptor that was not
bound to the cell wall but free to float in solution. This would act by competitive inhibition, 
attaching to the HRV before it would attach to the host cell’s ICAM-1 (Taubes, 1999). Human 
cells naturally make a form of sICAM-1, but HRV acts on the cell to upregulate the membrane
bound ICAM-1, and down regulates the sICAM-1 in the extracellular space, so that it can 
develop on the host cells and not be impeded by sICAM-1. So, a synthetic of sICAM-1, if
developed into a usable drug, could have a large effect. sICAM-1 has been proven to have
antiviral properties both in vitro in and in vivo (Whiteman, et al., 2002). The down regulation of
ICAM is so strong that although the ICAM right after ICAM infection is upgraded to prevent the
infection within the first 24 hours, it is almost immediately downgraded to the baseline level by 
day 9. The up regulation of ICAM is done in response to various stimuli, including ozone
exposure, interleukin-5, TNF alpha (tumor necrosis factor-alpha), interleukin-1, and CD8 T 
lymphocytes (Winther, et al., 2002). Hayden performed four clinical trials on 196 student
volunteers, with his version of soluble ICAM-1, known as Tremacamra. Virus shedding was 
detected from the experimentally induced HRV colds. Of the 177 subjects used to determine
efficacy, 81 received Tremacamra, and 96 received placebo. There was a 45 percent drop in 
symptoms, a 23 percent drop in the clinical colds, and a 56 percent drop in mucus, and above all, 
even if the drug was administered after infection, it still reduced symptoms, and it has
preventative measures (Turner, et al., 1999). A test in chimpanzees with rhinovirus-16 infection 
showed that the s-ICAM molecule was successful in preventing infection, through checking 
nasal washing and shedding (Huguenel, et al., 1997). Unfortunately, the development of
Tremacamra has been halted. The reason given has been the only marginal clinical benefit
observed in a highly controlled setting, with the drug being administered five to six times a day 
(McKinlay, 2001). 
SOLUBLE LDL
Soluble forms of the LDL receptor have also been tested, but not extensively, due to the
fact that only a few serotypes of HRV actually use the LDL receptor. It seems to inhibit infection 




        
       
       
           
         
     
        
           
 
 
     
       
    
         
          
          
        
     
   
     
     
        
        
  
       
       
       
        
       
          
         
         
     
    
 
 
      
   
        
         
             
       
The LDL receptor was analyzed and then a synthetic was developed, containing the seven 
low density-lipid receptor ligand binding repeats that were found on original LDL in cells. The
soluble LDL was tested against cells in vitro and found to bond to them, proving that the
synthetic was identical to the biological LDL. When the group of HRV that uses an LDL
receptor, HRV2, was tested against a synthetic soluble LDL receptor, it inhibited the HRV
infection in vitro. The virion particles formed large aggregates, preventing binding to the LDL
receptor in the host cell. In addition, some HRV particles were also prevented from binding to 
the host cell receptor due to competitive inhibition between the soluble LDL and the host cell
LDL. More investigation is probably necessary on this compound (Marlovits, et al., 1998).
AG7088-RUPRINTRIVIR
AG7088 has been synthesized at Agouron Pharmaceuticals in San Diego, and is an 
antiviral compound, which inhibits the 3C protease in HRV. It was originally tested with cells in 
the laboratory, and delivered statistically significant results in inhibiting infection by HRV
(Zalman, et al., 2000). And enzyme that is encoded by the virus, 3C protease, is the enzyme that
cleaves the viral proteins from the polyprotein molecule created in the first step of translation. 
This allows the virus to replicate and assemble itself. So, some low-molecular weight drugs have
been developed to inhibit the 3C protease and prevent HRV from translating. AG7088, one of
these drugs, shows good in vitro activity against HRV, and is now being reformulated to 
maximize delivery to the nasal cavity (Anzueto and Niederman, 2003). In fact, when tested, 
AG7088 showed that it irreversibly inhibits the 3C protease, preventing translation (Binford, et
al., 2004). It had been tested in 1999 on 868 subjects in a phase II study of naturally acquired 
picornavirus colds, and a trend was observed towards reduction of the total respiratory symptoms
(McKinlay, 2001). Ag7088 was found to be active against 48 HRV numbered serotypes as well
as 46 unnumbered types and 4 other picornaviruses (Binford, et al., 2004). 
This AG7088, or known as Ruprintrivir, has reduced the number of cold victims in its
study, from around 44 percent with HRV in the group to 70 percent on a placebo. It had no major 
side effects, just nasal irritation or blood-tinged mucus (Hayden, et al., 2003). Studies have
shown that AG7088 did not prevent experimental rhinovirus infection, but it reduced illness
severity. The side effects, nausea and taste disturbance, were mild (Greenberg, 2003). It was
given as a nasal spray, and positively reduced the proportion of those subjects with a positive
viral culture out of 202 subjects. The overall infection rate was reduced by 28 percent, but
although it has antiviral effects, it didn’t diminish the frequency of catching a cold (Hayden, et
al., 2003). As such, AG7088 is being reformulated to maximize its effects, and to allow better 
delivery to the nasal cavity (Greenberg, 2003), with further phase II trials in play (McKinlay, 
2001).
VIRAL CAPSID BINDING COMPOUNDS
There are many viral capsid binding compounds in existence, which have been used for 
picornavirus infections. These include amantadine, rimantadine, and zanamivir. However, with 
rhinoviruses, these drugs give no major clinical benefit. These drugs bind to the hydrophobic
pockets in HRVs capsid, and then inhibit the uncoating of the virus and attachment via ICAM-1. 
In addition, the side effects of most of these drugs outweigh the slight benefits they give against




          
     
      
  
    
        
       




            
      
       
       
       
       
     
       
     
      
 
   
        
 
 
     
     
       
    
   
        
      
       
       
 
       
         
 
 
antiviral activity, but most have not demonstrated the same in human clinical trials of HRV. 
Many of these compounds have limitations in dosing, delivery, tolerance, bioavailability, 
solubility, and safety, and as such, only preclinical trials re performed with these agents
(Anzueto and Niederman, 2003). 
A specific capsid-binding compound, BTA188, created in Australia, has been shown to 
inhibit antiviral activity. It had been tested, and inhibited 87 out of 100 specific serotypes of
HRV, although it has yet to be tested on humans. BTA188 has been tested on dogs and rodents, 
with antiHRV activity, and a good uptake of the compound by the cells in question. This
compound should undergo further testing and refining in the future (McKinlay, 2001).
ENVIROXIME
Enviroxime is an antiviral agent made from a benzimidazole derivative. It is believed that
enviroxime works by inhibiting the viral RNA polymerase replication complex, (Sperber and 
Hayden, 1988) thus targeting viral replication inhibition of the virus. It inhibited the 3A coding 
region of the viral RNA, not letting it be translated, and effectively shutting down the process. 
However, its development has been halted, because it cannot be administered orally, and in 
clinical studies when it was administered nasally, it had limited antiviral activity. However, other 
similar compounds are under investigation (Anzueto and Niederman, 2003). Side effects were
observed, like nausea and vomiting. There was limited antiviral activity in several trials. In a
study with our sprays per day, there was no benefit shown, with no reduction in viral shedding or 
symptoms, and a study with six sprays per day showed the same results. It was also tested on 
naturally occurring HRV colds, with no specific advantages or antiviral effects. 
However, although enviroxime had minimal antiviral effects, other similar compounds, 
like enviradene, are still under consideration, as are other methods of administering these
compounds, like a topical delivery (Sperber and Hayden, 1988).
PIRODAVIR
Pirodavir, a substituted phenoxy-pyridanzinamine, is a compound that possesses anti-
picornavirus activity (Tolan, et alk., 2007). Several pyridazinamines, like R61837, have already 
been tested to have clinical activity against many serotypes. It binds to the HRV capsid, and 
prevents capsid uncoating, cumulating in no infection. Four double-blind trials were performed
on volunteer subjects experimentally induced with HRV colds, and pirodavir was administered 
intranasally. When sprays were given six times a day, colds developed in 100 percent of the
placebo subjects, while only 58 percent of the pirodavir treated subjects became infected. 
Pirodavir also was associated with an unpleasant taste, but that was the only serious complaint. 
However, it would have to be administered with frequent nasal sprays daily during the duration 
of a cold (Hayden, et al., 1992). 
However, clinical trials have not shown any decrease in rhinovirus viral shedding or 
symptoms, and as such, it has not been used for HRV (Tolan, et al., 2007). It was effective when 





            
          
       
    
     
 
    
      
           
       
       
   
 
       
     
     
       
          
              
         
           
          
 
   
          
      
      
      
        
 
 
           
     
      
       
        
        
 
 
         
      
       
There have been many studies done on the anti-viral effects of zinc on HRV. Some show
that zinc beneficial, and some don’t. Zinc’s mode of anti-viral action is still subject to much 
discussion, although several theories include competitive inhibition, which prevents the HRV
from binding to ICAM-1 blocking viral entry in to the cells, inhibiting viral capsid protein 
synthesis, stabilizing the membrane of the host cell, inhibiting prostaglandin metabolites, and 
increasing interferon production in the host cell (Mossad, 1998).
According to one study done on acute power upper respiratory infections, primarily 
caused by rhinoviruses, zinc gluconate lozenges were given to volunteers, and the duration of
illness was not significantly reduced. The severity of the illness was reduced, but the adverse
side effects, like nausea and altered taste, were reported by fifty percent of the volunteers. 
Therefore, according to that study, zinc lozenges were ineffective. The authors concluded that
zinc had prevented rhinovirus replication by complexing with the capsid proteins, and preventing 
the proteases from binding to them (Smith, et al., 1989).
A study was performed by one group who found 40 percent reduction in symptoms, but
they used unflavored zinc gluconate tablets and unflavored calcium tablets, leading to a
difference in taste (Eby, et al., 1984). Another study performed also found significant reductions
in symptoms by using zinc lozenges, but found no antiviral effects. This may have been due to 
the nasal washings used to dilute a sample for testing may have removed from the zinc, and the
effect of zinc may have been only due to the actual presence of zinc in the sample at the time, 
instead of having an effect once it had just touched the viral sample, and didn’t need to be
actually present (Al Nakib, et al., 1987). It could be that the efficacy of the lozenge is related to 
the saliva concentration of zinc, and as such, the saliva can’t impact the nasal mucosa, leaving 
most HRVs untouched, making all the lozenge studies invalid (Eby, 1988).
According to another study done by Gwaltney, Farr and colleagues, who tested zinc
lozenges as well, zinc therapy did not reduce the viral symptoms, or alleviate the cold manifest
symptoms. This study concluded that participants in other studies may have tasted the bad-
tasting zinc lozenges and ascribed healing benefits towards them unduly, and as such, they 
developed a taste-matched placebo that also tasted bitter to prevent the volunteers from realizing 
which tablet was the active medication. They found that zinc truly had no noticeable effect (Farr, 
et al., 1987).
MAST CELL STABILIZERS
Mast cell stabilizers are those drugs like Nedocromil and sodium cromoglycate. They are
administered intranasally or inhaled, and have reduced the severity of natural and experimental
HRV colds. However, they prevent the chemokines and cytokines from being released, reducing 
symptoms, but they also do a small part in down regulating the ICAM-1 receptor, so the virus
can’t bond to the host cell. They have been shown to have no effect on viral shedding or viral
response to the infection, so although they have some anti-viral effects, it is minimal (Mossad, 
1998).
AQUEOUS IODINE
There have been many studies and arguments, some of which that are still going on 
regarding the method of transmission of HRV. In the University of Virginia, Jack Gwaltney 




    
    
       
      
       
       
    
       





      
      
          
      
   
  
      
      
     
   
           
          
 
 
     
         
      
     
    
      
       
      
   
 
     
      
          
         
Owen Hendley, developed an iodine solution that killed the virus through hand contact. 
However, the solution smelled bad, and turned skin brown, but those who used the solution had 
40 percent fewer colds. Elliot Dick of the University of Wisconsin, developed what was known 
as virucidal facial tissues, known as Dr. Dick’s Killer Kleenexes, D2K2 for short. In a test, 60 
percent of those who used cloth handkerchiefs developed a cold. Elliot Dick also tested for the
mode of transmission. He discovered that HRV developed through aerosol contact, not through 
touch, through an experiment with human volunteers. The D2K2 tissues were marketed under 
‘Avert’, from the Kleenex Company, but didn’t sell so well. In addition, Gwaltney, the chief
proponent of the touch transmission hypothesis found that they only worked 10 percent of the
time in his study (Radetsky, 1991). 
ACID SOAKED TISSUES
Jack Gwaltney, along with his colleagues, developed the virucidal nasal tissues. These
were nasal tissues, like Kleenex, that had been impregnated with malic and critic acids, along 
with sodium lauryl sulphate. The idea was to reduce the pH in the nasal cavity, causing 
spontaneous capsid disassembly to prevent HRV infection. Working against a placebo of
saccharin acid, they caused a 14 percent drop in cold infection rate. So, when used, these
virucidal tissues may have a small effect, but not a major one (Farr, et al., 1988). 
Gwaltney continued to submit his theory developed in 1978 that HRV was transmitted by 
hand to hand contact. Although iodine is probably the most effective in preventing the spread by 
touch, it comes with side effects listed earlier…Under Patent 6034133, Jack Gwaltney, Owen 
Hendley, and Deborah Thacker registered their idea for a virucidal hand lotion, which contained 
the same ethyl alcohol, citric acid, and malic acid of the tissues, and was not dangerous to the
skin. According to a study done against iodine, this lotion was just as effective at halting the
spread of the virus, due to lowering the pH to around 3 (Hendley, et al.-Patent, 2000).
ANTIBIOTICS
According to studies, although antibiotics are commonly prescribed for HRV, there is no 
clinical benefit or antiviral activity. A study of 1,500 children found that antibiotics did not affect
the HRV caused colds. Some cold sufferers, around 20 percent, according to a Swiss study, have
pathogenic respirator bacteria, like streptococcus pneumonia, Haemophilus influenzae and 
Moraxella catarrhalis, for which the antibiotics may be helpful, especially if treated with 
amoxicillin clavulanate. However, for those patients without bacteria, the antibiotics do not help, 
and in fact, cause five times more gastrointestinal intolerance and reactions. So, antibiotics
should not be prescribed for HRV (Rotbart and Hayden, 2000). However, doctors continue to 
prescribe unnecessary antibiotics, leading to $37.5 million in 1994 spent for HRV related 
prescription of antibiotics, contributing to drug-resistant bacteria (Mossad, 1998). 
Several studies continue to have been performed, using demethylchlortetracycline, 
amoxicillin and cotrimoxazole, and cephalexin. The effects for all these studies were mostly 
gastrointestinal, but most had positive effects. According to a review of all the studies, it states




             
 
        
      
           
          
 
       
      
      
      
           
       
 
     
      
 
        
       
       
 
 
     
   
   
       
     
           
      
             
 
 
      
      
     
     
 
  
     
            
           
antibiotics’ as the first line of defense due to the unclear studies and the side effects (Arroll and 
Kenealy, 2006).
A study was done on 109 patients with COPD (chronic obstructive pulmonary disease), 
and were observed for twelve months while receiving erythromycin therapy. The results showed 
that 76 percent of those who did not receive the therapy caught a cold while 13 percent who 
received the erythromycin therapy caught a cold and since HRV is the major cause of the
common cold, antibiotics may be beneficial (Suzuki, et al., 2001). 
In a recent study, the antibiotic erythromycin did inhibit HRV infection in tracheal
epithelial cells. It reduced the susceptibility of reinfection, the nuclear factor-kB activation, the
number of acidic endosomes, and the cytokine production. The study suggested that
erythromycin reduces the ICAM-1 receptor and blocks the rhinovirus’ entry into the cell by way 
of the endosomes. This is the first time that macrolide antibiotics have actually helped in an 
experimental way. However, when clinical trials were performed, the macrolide antibiotic did no 
better than a regular antibiotic, trimethoprim-sulfamethoxazole (Suziki, et al., 2002).
Corticosteroids have been shown to inhibit the rhinovirus action through inhibiting 
interleukin activity, specifically NF-kappa B activity, but these steroids actually increase virus
replication, having no anti-viral activity as was once thought (Turner, 2000). 
NF-Kappa B is a substance used to indicate to cells to produce tumor necrosis factor-
alpha. This factor, TNF-alpha, is used to exacerbate virus infections by starting the body’s
immune responses. When HRV infects the cells, stimulating macrophages, these factors are
released, leading to the inflammatory responses (Laza-Stanca, et al., 2006).
NITRIC OXIDE
When HRV attacks a human system, it caused interleukin production, specifically IL-8 
and IL-6, causing inflammatory measure. However, when a nitric oxide donor, specifically 3-(2-
hydroxy-2-nitroso-1-proplyhydrazino)-1 propanamine, also known as NONOate, was applied, it
inhibited the rhinovirus replication and the cytokine production from the body by releasing nitric
oxide. This nitric-oxide releasing effect may have both an anti-inflammatory and an antiviral
effect (Sanders, et al., 1997). It seems likely that the release of NO may inhibit early events in 
the viral infection process. NO has been tested in other picornaviruses, and had an effect against
the replication of these viruses, and as such, further testing will be done to see it is has the same
effect on HRV (Sanders and Proud-patent, 1998).
R61837
R61837 is another compound that inhibits the replication of rhinoviruses. When tested in 
vitro, it inhibited 74 percent of the HRV serotypes. When administered intranasally in frequent
dosages, starting 1 hour before an HRV cold infected a subject and continuing for six days
afterwards, it reduced the symptoms and mucus production, along with inhibiting the replication 
process. Further studies on this compound need to be done (Sperber and Hayden, 1988).
PDTC
PDTC, or pyrrolidine dithiocarbamate, is another antiviral compound, which works
against all tested HRV serotypes yet. However, the studies are not conclusive as to how exactly it




      
    
      
          
 
 
           
     
         
            
       
 
        
        
 
       
        
    
 
 
   
         
          
         
       
        
        
        
         
 
  
          
            
          
       
         
       
       
        
  
adding metal ions to PDTC blocks its antiviral effects. PDTC actually inhibits NF-kappa, which 
had been adding metal ions to PDTC actually inhibits NF-kappa B, which had been mentioned 
earlier, and PDTC inhibits the polyprotein processing of HRV. However, how it accomplishes
this is still not understood. More research on this antiviral drug is needed to come to more
conclusive results (Krenn, et al., 2005).
NATURAL REMEDIES
There have been some natural anti-viral remedies as well for rhinovirus. A Chinese herb 
Agastache folium, had been used for the common cold, and a company named Roche extracted a
chemical from the herb that stopped HRV from multiplying within cells. It binds to the capsid 
surface of rhinoviruses to prevent them from infecting a host cell by binding to the host cell
receptor. However, its effect and anti-viral activity is not well known yet, and the chemical, Ro-
09-0415 is undergoing testing (Scott, 1987).
Ro-09-0415 is actually a phosphorylated ester attached to the original antiviral flavone
from the Chinese herb. It seemed to absorb well, but ineffective eventually, in large dosages, like
1200 mg attached to cells (Sperber and Hayden, 1988).
A different capsid binding agent, Ro-09-0410, was developed, also from the same
compound. It also seemed to have adequate levels in blood, but the drug was undetectable in 
nasal washings, and seemed to have no anti-viral effect, and actually increased mucous
production, which didn’t alleviate symptoms (Sperber and Hayden, 1988).
DICHLOROFLAVAN
Dichlorofalvan is another capsid-binding agent, preventing viral uncoating and 
attachment to the host cell receptor. It inhibited viral activity best when it was added together 
with the virus, but it did show antiviral activity even when it was added replication of a single
cycle of HRV (Tisdale and Selway, 1983). When it was administered orally three times daily, it
was ineffective in inhibiting HRV infection. When tested in nasal washings, it was not detected, 
despite adequate levels of the drug administered. When it was administered intranasally, a high 
level of the drug was detected, proving that intranasally was the correct application. However, 
when the nasal drops were administered five times daily, they failed to reduce HRV infections, 
showing that adequate levels of the drug were not taken up by nasal cells (Sperber and Hayden, 
1988).
CONCLUSION AND SUMMARY
Rhinoviruses are one of the most common and well known pathogens to date. They were
the first virus crystal structure mapped, and the quest for the cure for the common cold is well
known and documented, including its mode of attack, and how it affects a host cell. There are
even many old proverbs regarding rhinoviruses that have sprung up since ancient times. From
England, “stuff a cold starve a fever”, from Germany, “sauerkraut is good”, and from India, “one
cold in the head is as bad as ten diseases’. Many doctors go by the proverb, “untreated colds last 
a week; medical attention can end them after seven days” (Biddle, 2002). William Osler, a John 
Hopkins doctor, stated “there is just one way to treat the common cold-with contempt”. For colds
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